UBS initiated coverage on Regeneron Pharma (NASDAQ: REGN) with a Neutral rating and a price target of $290.00. Analyst Matthew ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE